Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses-Reference-Cited by-同舟云学术

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses

Published:2023-11 Issue: Volume: Page:
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Armuzzi Alessandro^ORCID,Cross Raymond K.,Lichtenstein Gary R.,Hou Jason,Deepak Parakkal,Regueiro Miguel,Wolf Douglas C.,Akukwe Lucy,Ahmad Harris A.,Jain Anjali,Kozinn Marc,Wu Hsiuanlin,Petersen AnnKatrin,Charles Lorna,Long Millie

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference32 articles.

1. Zeposia [package insert],2023

2. Zeposia [summary of product characteristics],2023

3. Ozanimod: a first-in-class sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis;Choi;Ann Pharmacother,2022

4. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity;Scott;Br J Pharmacol,2016

5. Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT/QTc study;Tran;Clin Pharmacol Drug Dev,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning;Clinical Gastroenterology and Hepatology;2024-08

2. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond;Expert Opinion on Pharmacotherapy;2024-03-23